Abstract-Glucagon, a major insulin counterregulatory hormone, binds to specific G s protein-coupled receptors to activate glycogenolytic and gluconeogenic pathways, causing blood glucose levels to increase. Inappropriate increases in serum glucagon play a critical role in the development of insulin resistance and target organ damage in type 2 diabetes. We tested the hypotheses that: (1) glucagon induces proliferation of rat glomerular mesangial cells through glucagon receptor-activated phosphorylation of mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 (p-ERK 1/2); and (2) 
T he pancreatic hormone glucagon is a 29-amino acid peptide that is synthesized in ␣ cells at the periphery of the islets of Langerhans and released primarily in response to low blood glucose levels (hypoglycemia). 1, 2 Glucagon binds to its specific G s protein-coupled receptors to activate glycogenolytic and gluconeogenic pathways, causing blood glucose levels to increase. 2 The primary action of glucagon is to counter the glucose-lowering effect of insulin, which is synthesized and released by pancreatic ␤ cells. 2 Imbalance between the effects of insulin and glucagon on glucose metabolism because of insulin deficiency clearly contributes to the development of type 1 diabetes in humans. 3 However, clinical studies have shown that patients with type 2 diabetes do not have insulin deficiency; rather, they exhibit either normal or elevated fasting glucagon levels (hyperglucagonemia) that are unable to decrease appropriately in response to glucose intake. [3] [4] [5] [6] Thus, increased serum glucagon relative to insulin is responsible for elevated serum glucose levels (hyperglycemia) and, consequently, for increased insulin resistance and development of target organ damage in human type 2 diabetes. 3, 5, 7 Although the role of glucagon in the regulation of blood glucose is well documented, its potential to cause target organ damage in type 2 diabetes remains poorly understood. 2, 3 In the kidney, glucagon induces glomerular hyperfiltration, a characteristic of early type 2 diabetic glomerular injury. 8 -11 Infusion of glucagon at levels reported in type 2 diabetes increased the glomerular filtration rate (GFR) by Ϸ50%, 8 -11 whereas an antibody that neutralizes glucagon decreased GFR in rats with streptozotocin-induced diabetes. 12 Persistent glomerular hyperfiltration induced by glucagon may lead to glomerular injury by stimulating growth and proliferation of mesangial cells (MCs) with subsequent mesangial expansion and glomerulosclerosis. 13 However, it is not known whether glucagon directly stimulates MC proliferation and activates mitogen-activated protein kinase (MAPK) signaling.
In the present study, we tested the following hypotheses: (1) glucagon induces proliferation of rat MCs through gluca-gon receptor-activated MAPK extracellular signal-regulated kinase (ERK) 1/2 signaling pathways; and (2) glucagoninduced ERK 1/2 signaling involves activation of phospholipase C and cAMP-dependent protein kinase A (PKA). We believe that our data show for the first time that glucagon exerts a proliferative effect on rat glomerular MCs by activating glucagon receptors and inducing MAPK ERK 1/2 phosphorylation and that glucagon-induced MC proliferation and ERK 1/2 phosphorylation require cAMP-dependent PKA-and PLC-activated signaling.
Methods

MC Culture
Rat glomerular MCs were obtained from American Type Culture Collection. The cells were maintained in RPMI-1640 medium (10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 2 mmol/L L-glutamine, 5 mmol/L glucose, and 1500 mg sodium bicarbonate/L; ATCC) containing 12% fetal calf serum (ATCC), penicillin (100 U/mL), and streptomycin (100 g/mL) at 37°C in 5% CO 2 /95% O 2 . 14 MCs from passages 6 to 10 were subcultured in 6-well plates containing the above growth medium until they reached 80% confluence and maintained in serum-free medium for 24 hours before the experiment. Unless otherwise specified, all of the experiments were performed in serum-free medium with or without glucagon or other blockers.
Glucagon Receptor Binding and Receptor-Mediated Signaling in MCs
Glucagon receptor binding or mRNA expression has been reported in cultured or microdissected renal tubules. 15, 16 To determine whether glomerular MCs express functional glucagon receptors, subconfluent MCs were incubated with 100 pmol of 125 I-labeled glucagon (specificity: Ϸ2000 Ci/mmol, Biochem) for 60 minutes at 37°C in a binding buffer containing 50 mmol/L HEPES, 1 mmol/L MgCl 2 , 5 mmol/L EGTA, 0.2% BSA, and EDTA-free protease inhibitor mixture (Roche). 15, 16 After incubation, the buffer was removed, and MCs were washed twice with 2 mL ice-cold buffer without BSA. The cells were then collected in tubes and harvested by rapid filtration using a 48-well cell harvester (Brandel). To determine whether glucagon binds to its specific receptors to induce cell signaling, we measured intracellular cAMP accumulation and [Ca 2ϩ ] i mobilization in response to glucagon stimulation. Subconfluent MCs cultured in 6-well plates were treated with vehicle (serum-free medium), glucagon (1 nM), or glucagon plus [Des-His1-Glu9] glucagon (1 mol/L). The phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (1 mmol/L) was added to all of the samples to prevent cAMP degradation. [17] [18] [19] After treatment, the medium was removed, and the cells were washed and lysed with 0.1 N HCl. The lysates were centrifuged at 1000g, and cAMP levels in supernatants were determined using a sensitive cAMP ELISA kit (R&D).
To (1 mol/L) using the calcium indicator dye fura 2 (Molecular Probes). 20 MCs grown on coverslips were loaded with fura 2 (2 mol/L) for 30 minutes at 37°C. After washes, coverslips were mounted on a perfusion chamber maintained at 37°C, which, in turn, was mounted on a Nikon Eclipase TE 2000-U fluorescence microscope coupled with a Lambda DG4 illumination system (Sutter Instruments). Ratiometric calcium responses were continuously recorded at 3-second intervals for up to 10 minutes. 
Effects of Glucagon on MC Proliferation
To determine whether glucagon directly stimulates MC proliferation, we measured [
3 H]-thymidine incorporation, an index of DNA synthesis and cell proliferation. 21 MCs were split into 6-well plates and incubated in RPMI-1640 medium (10 5 /well). Subconfluent MCs were treated with serum-free medium (control; nϭ6 wells), glucagon (1 nM, nϭ6 wells), glucagon plus [Des-His1-Glu9] glucagon (1 mol/L, nϭ6 wells), glucagon plus PD98059 (10 mol/L, nϭ6 wells), a specific inhibitor of the MAPK/ERK (the upstream kinase of ERK 1/2), 17 glucagon plus U73122 (1 mol/L, nϭ6 wells), or glucagon plus H-89 (1 mol/L, nϭ6 wells) and pulsed with 1 Ci/mL [ 3 H]-thymidine for 24 hours. After treatment, the medium was removed, and MCs were washed with ice-cold PBS and lysed with 200 mmol/L NaOH and 0.25% SDS. The contents were transferred to tubes, vacuum filtered, and washed 4 times with 5 mL ethanol/trichloroacetic acid (70%/5%) using a Brandel cell harvester.
Incorporated [
3 H]-thymidine was counted in vials containing 4 mL of scintillation mixture. 21 
Concentration-and Time-Dependent Effects of Glucagon on ERK 1/2 Phosphorylation in MCs
Agonist-induced phosphorylation of cytoplasmic serine/threoninecontaining MAPKs plays an important role in cell differentiation, proliferation, and transformation. [21] [22] [23] To determine whether glucagon induces ERK 1/2 phosphorylation in MCs, subconfluent cells were treated with either serum-free medium or increasing concentrations of glucagon (0, 0.1, 1.0, or 10.0 nM) for 0 minutes to 2 hours. Then, the medium was removed, and MCs were washed twice with ice-cold PBS and lysed with Nonidet P-40 lysis buffer containing the inhibitor mixture (Roche). Protein was measured using a BCA protein assay kit (Pierce). Protein (10 g) from each sample was separated on 8% to 16% SDS/polyacrylamide gel and transferred semidry onto an Immobilon-P membrane (Millipore). Total and phosphorylated ERK 1/2 were detected by immunoblotting using a rabbit ERK 1/2 polyclonal antibody against the C terminus of rat ERK 1/2 or a mouse antiphosphorylated ERK 1/2 monoclonal antibody against an amino acid sequence containing phosphorylated Tyr-204 of human ERK 1/2 (Santa Cruz). Western blot of ␤-actin (Sigma) was used to confirm equal protein loading. Immunoblots were visualized by enhanced chemiluminescence using horseradish peroxidase-conjugated secondary antibodies (Santa Cruz), 21, 23 scanned and analyzed using a microcomputer imaging device (Imaging Research).
Role of Glucagon Receptor-Activated cAMP-Dependent PKA or PLC Signaling in Glucagon-Induced ERK 1/2 Phosphorylation
On binding to specific G protein-coupled receptors, glucagon activates 2 major intracellular signaling pathways, cAMP-dependent PKA and PLC, leading to increased levels of cAMP and [Ca 2ϩ ] i . 2, 20, 22 To determine whether these 2 signaling pathways are involved in glucagon-induced ERK 1/2 phosphorylation, subconfluent MCs were treated with glucagon alone (1 nM, nϭ6 wells) or pretreated with the potent PKA-selective inhibitor H-89 (1 mol/L, nϭ6 wells) or the potent PLC-selective inhibitor U73122 (1 mol/L, nϭ6 wells) for 30 minutes before glucagon stimulation. Protein samples were extracted for Western blot of total and phosphorylated ERK 1/2.
Statistical Analysis
Where appropriate, results were expressed as meanϮSEM. The differences between groups were compared using 1-way ANOVA followed by Dunnett's post hoc test. PϽ0.05 was taken as significant. Figure 1A) . The B max averaged 1192Ϯ40 pmol/mg protein. These binding sites were displaced in a concentration-dependent manner by excess unlabeled glucagon or its antagonist [Des-His1-Glu9] glucagon (10 mol/L) with a log IC 50 value of 1.26Ϯ0.36 nM and 10.1Ϯ0.44 nM, respectively, indicating that they are specific for glucagon ( Figure 1A 
Results
Glucagon
). Exposing MCs to glucagon for 30 minutes led to a 4-fold increase in intracellular cAMP accumulation (
Concentration-and Time-Dependent Effects of Glucagon on MAPK ERK 1/2 Phosphorylation
We tested the hypothesis that glucagon directly activates one of the most important downstream MAPK signaling cascades, ERK 1/2 phosphorylation. Treating MCs with glucagon led to a concentration-dependent increase in ERK 1/2 phosphorylation, reaching a maximum at 10 nM (Figure 3) . Based on the concentration-dependent responses, we used 1 nM glucagon for subsequent experiments, because the K d of the glucagon receptor is reportedly close to this concentration. 24 Glucagon at 1 nM induced rapid ERK 1/2 phosphorylation beginning at 2 minutes (data not shown) and peaking at 5 minutes of stimulation (Figure 4 
Discussion
We believe the present study demonstrates for the first time that rat MCs express specific functional glucagon receptors that, when activated, increase intracellular cAMP accumulation and [Ca 2ϩ ] i , 2 important signaling pathways for glucagon. It also activates its specific receptors to stimulate MC proliferation by increasing [ 3 H]-thymidine incorporation, associated with increased MAPK ERK 1/2 phosphorylation. Glucagon-induced ERK 1/2 phosphorylation was both dose and time dependent and appeared to involve both the cAMPdependent PKA-and PLC-activated IP 3 /[Ca 2ϩ ] i signaling. Because activation of MAPK ERK 1/2 signaling and increased DNA synthesis play important roles in various vasoactive peptide-or cytokine-induced cellular growths and proliferations, our results suggest that the unique action of glucagon on MC proliferation and ERK 1/2 phosphorylation may contribute to the development of glomerular or mesangial injury in type 2 diabetes.
Specific glucagon receptor binding or mRNA has been reported in isolated nephron segments, including the proximal tubule, loop of Henle, and cortical collecting duct. 15, 16 Using RT-PCR, Marks et al 16 detected similar levels of glucagon receptor mRNA expression in the glomerulus; however, it is not known whether MCs express functional glucagon receptors. In the renal cortex, the primary effect of glucagon is to increase glomerular filtration. 8, 9 We have shown previously that glucagon-induced glomerular hyperfiltration is comparable to that caused by atrial natriuretic peptide in rats. 9, 25 Glucagon is believed to be responsible for increased GFR after a high-protein meal or the glomerular hyperfiltration seen in early stages of diabetes. 10 Although MCs may, therefore, represent a major target of glucagon in the glomerulus, it remains unclear whether glucagon has a direct effect on MCs or the signaling mechanism(s) involved. The present study provides evidence that MCs express functional glucagon receptors. Using 125 I-glucagon radioreceptor binding assays, we found high levels of 125 I-glucagon receptor binding in MCs ( Figure 1A) . Binding was considered specific for glucagon, because it was readily displaced by an excess (1 mol/L Glucagon has long been implicated in the development of target organ damage in diabetes, because it opposes the actions of insulin by inducing hyperglycemia. 7 Hyperglycemia has been shown to promote cellular growth and proliferation and increase production of extracellular matrix proteins in MCs and vascular smooth muscle cells. 14, 26, 27 The progrowth and proliferative effects of high glucose appear to be mediated by activation of the MAPKs, including ERK 1/2, c-Jun N-terminal kinase, and p38. 14,26 -28 However, direct effects of glucagon on MC proliferation and activation of ERK 1/2 have not been reported to our knowledge. In the present study, we demonstrated that glucagon directly stimulated [ 3 H]-thymidine incorporation, and this effect was completely blocked by the glucagon receptor antagonist [Des-His 1 -Glu 9 ] glucagon and the MAPK inhibitor PD98059 (Figure 2) . The proliferative effect of glucagon on MCs was likely mediated by glucagon receptor-activated ERK 1/2 signaling. Glucagon induced phosphorylation of ERK 1/2 in MCs in a dose-and time-dependent manner, and pretreating MCs with the glucagon receptor blocker completely abolished these effects. Our results are consistent with previous reports that glucagon or glucagon-like peptide 1 activated ERK 1/2 signaling in stable cell lines (HEK 293 cells or pancreatic ␤ cells) expressing the glucagon receptor. 29, 30 The glucagon receptor represents a family of G s proteincoupled receptors, and binding of the agonist to the receptor activates 2 classical signaling pathways, adenylyl cyclase and PLC, leading to increased intracellular cAMP and [Ca 2ϩ ] i . 2 In turn, PLC signaling-mediated increase in [Ca 2ϩ ] i and diacylglycerol levels activate protein kinase C to induce MAPK phosphorylation. 2 Increased cAMP can also induce MAPK phosphorylation by activating downstream PKA. 17, 22 In HEK 293 cells stably expressing the glucagon receptor, glucagon was shown to activate cAMP-dependent PKA, and depletion of intracellular [Ca 2ϩ ] i stores blocked glucagon-induced ERK 1/2 phosphorylation. 22 Our results show that glucagoninduced ERK 1/2 phosphorylation in MCs also requires 
Perspectives
We believe that the present study demonstrates for the first time that glucagon activated specific receptors to increase MC proliferation by stimulating MAPK ERK1/2 phosphorylation and that these effects of glucagon are dependent on activation of PLC/[Ca 2ϩ ] i -and cAMP/PKA-mediated signaling cascades. Together with the well-documented effects of glucagon on glomerular hyperfiltration, direct growth and proliferative effects of glucagon on MCs and underlying signaling mechanisms may have important clinical implications in the development and treatment of type 2 diabetic glomerular injury. Because plasma insulin levels remain relatively normal, whereas plasma glucagon levels are inappropriately elevated in type 2 diabetes, our results support the concept that pharmacological blockers or molecular intervention targeting glucagon and/or its receptors may be a useful approach in the clinical prevention and treatment of target organ damage in type 2 diabetes.
